HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Apple Restores Telegram to App Store After Content Policy Violation 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Telegram Restored on Apple App Store After Temporary Removal 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
CANTON, Mass., April 04, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 10, 2018 at 11:55 a.m. CET at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact:
Alex Dasalla
[email protected]
